\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ is\\ normal\\ except\\ for\\ mild\\ tenderness\\ to\\ palpation\\ over\\ the\\ left\\ posterior\\ ribs\\.\ \(0\)\
\-\ current\\ treatment\\ for\\ multiple\\ myeloma\\ is\\ initial\\ combination\\ chemotherapy\\ and\\ other\\ medication\\ such\\ as\\ steroids\\ or\\ thalidomide\\ for\\ cytoreduction\\ followed\\ by\\ bone\\ marrow\\ transplantation\\ \\(3\\)\\.\\ recent\\ studies\\ have\\ shown\\ the\\ bisphosphonates\\ decrease\\ the\\ incidence\\ of\\ pathologic\\ fractures\\.\\ patients\\ are\\ followed\\ with\\ skeletal\\ surveys\\ to\\ evaluate\\ for\\ response\\ to\\ therapy\\ and\\ disease\\ progression\\.\\ \\ bone\\ scans\\ are\\ usually\\ negative\\ with\\ multiple\\ myeloma\\.\\ ct\\ and\\ mri\\ can\\ be\\ used\\ to\\ define\\ the\\ lesions\\ more\\ accurately\\.\\ the\\ new\\ technique\\ of\\ total\\ body\\ mri\\ may\\ become\\ useful\\ for\\ evaluating\\ the\\ extent\\ of\\ disease\\ on\\ one\\ study\\(4\\)\\.\ \(0\)\
\-\ 1\\.\\ \\ a\\-p\\ radiograph\\ of\\ the\\ lower\\ ribs\\ shows\\ an\\ expansile\\ lytic\\ lesion\\ of\\ the\\ left\\ tenth\\ rib\\.\ \(0\)\
\-\ 2\\.\\ a\\-p\\ radiograph\\ of\\ the\\ pelvis\\ shows\\ lytic\\ lesions\\ of\\ both\\ acetabular\\ regions\\.\ \(0\)\
\-\ 3\\.\\ \\ lateral\\ radiograph\\ of\\ the\\ skull\\ shows\\ lytic\\ lesions\\ \\ in\\ the\\ temporoparietal\\ region\\.\ \(0\)\
\-\ multiple\\ myeloma\ \(25\)\
\-\ metastatic\\ disease\\,multiple\\ myeloma\ \(0\)\
\-\ 55\\ y\\/o\\ african\\-american\\ female\\ \\ presents\\ with\\ left\\ hip\\ and\\ rib\\ pain\\ on\\ follow\\-up\\ visit\\ for\\ known\\ disease\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ myeloma\\:\\ 0\\.10508721316944845\ \(0\)\
\-\ a\\-p\\:\\ 0\\.062127824812699024\ \(0\)\
\-\ lytic\\:\\ 0\\.06071564820932955\ \(0\)\
\-\ ribs\\:\\ 0\\.04879180745582574\ \(0\)\
\-\ rib\\:\\ 0\\.04520871578514809\ \(0\)\
\-\ radiograph\\:\\ 0\\.04320553418922798\ \(0\)\
\-\ thalidomide\\:\\ 0\\.04297550922437329\ \(0\)\
\-\ cytoreduction\\:\\ 0\\.04297550922437329\ \(0\)\
\-\ surveys\\:\\ 0\\.04297550922437329\ \(0\)\
\-\ tenth\\:\\ 0\\.039308063824585224\ \(0\)\
\-\ temporoparietal\\:\\ 0\\.03812741011392803\ \(0\)\
\-\ multiple\\:\\ 0\\.03809113234876759\ \(0\)\
\-\ shows\\:\\ 0\\.03729164602744252\ \(0\)\
\-\ lesions\\:\\ 0\\.03631048422768171\ \(0\)\
\-\ bisphosphonates\\:\\ 0\\.03395567804850861\ \(0\)\
\-\ accurately\\:\\ 0\\.03231464668182163\ \(0\)\
\-\ followed\\:\\ 0\\.030316146787076944\ \(0\)\
\-\ define\\:\\ 0\\.03028823264872054\ \(0\)\
\-\ transplantation\\:\\ 0\\.03005303813776375\ \(0\)\
\-\ acetabular\\:\\ 0\\.029611865603694693\ \(0\)\
\-\ disease\\:\\ 0\\.029560582882872045\ \(0\)\
\-\ african\\-american\\:\\ 0\\.029204664327842165\ \(0\)\
\-\ technique\\:\\ 0\\.02605131283521625\ \(0\)\
\-\ visit\\:\\ 0\\.025944420203906624\ \(0\)\
\-\ evaluating\\:\\ 0\\.02515912917153481\ \(0\)\
\-\ useful\\:\\ 0\\.023591585170777283\ \(0\)\
\-\ for\\:\\ 0\\.023146290433102065\ \(0\)\
\-\ except\\:\\ 0\\.022893555842509832\ \(0\)\
\-\ combination\\:\\ 0\\.022775973108199198\ \(0\)\
\-\ medication\\:\\ 0\\.022775973108199198\ \(0\)\
\-\ response\\:\\ 0\\.022660946723879586\ \(0\)\
\-\ progression\\:\\ 0\\.022492964193114615\ \(0\)\
\-\ bone\\:\\ 0\\.022470208269416612\ \(0\)\
\-\ extent\\:\\ 0\\.022438134632079974\ \(0\)\
\-\ skeletal\\:\\ 0\\.02233015118429581\ \(0\)\
\-\ expansile\\:\\ 0\\.022172198998318658\ \(0\)\
\-\ 55\\:\\ 0\\.02191899253706133\ \(0\)\
\-\ become\\:\\ 0\\.02153749362753041\ \(0\)\
\-\ steroids\\:\\ 0\\.021268401472855854\ \(0\)\
\-\ current\\:\\ 0\\.021181661738593018\ \(0\)\
\-\ scans\\:\\ 0\\.021054161465687938\ \(0\)\
\-\ mri\\:\\ 0\\.02077540587211238\ \(0\)\
\-\ incidence\\:\\ 0\\.020728458328124796\ \(0\)\
\-\ decrease\\:\\ 0\\.020689119817608827\ \(0\)\
\-\ regions\\:\\ 0\\.020689119817608827\ \(0\)\
\-\ marrow\\:\\ 0\\.019890331315440157\ \(0\)\
\-\ pathologic\\:\\ 0\\.01979018311498768\ \(0\)\
\-\ total\\:\\ 0\\.019469417920191724\ \(0\)\
\-\ skull\\:\\ 0\\.019255919002077612\ \(0\)\
\-\ evaluate\\:\\ 0\\.01827632940876758\ \(0\)\
\-\ shown\\:\\ 0\\.018129347588095222\ \(0\)\
\-\ hip\\:\\ 0\\.018009906730748457\ \(0\)\
\-\ used\\:\\ 0\\.017344889719301385\ \(0\)\
\-\ fractures\\:\\ 0\\.01712057459248823\ \(0\)\
\-\ studies\\:\\ 0\\.016886248242217777\ \(0\)\
\-\ pelvis\\:\\ 0\\.01642905506133137\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.016206062355242672\ \(0\)\
\-\ new\\:\\ 0\\.015755491940743695\ \(0\)\
\-\ 3\\.\\:\\ 0\\.015470233926670515\ \(0\)\
\-\ recent\\:\\ 0\\.015199571686983052\ \(0\)\
\-\ left\\:\\ 0\\.01517627411544309\ \(0\)\
\-\ palpation\\:\\ 0\\.015089624763746305\ \(0\)\
\-\ initial\\:\\ 0\\.01498191610200692\ \(0\)\
\-\ study\\:\\ 0\\.014876356385502429\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.014709190430908688\ \(0\)\
\-\ body\\:\\ 0\\.014683934987772932\ \(0\)\
\-\ 2\\.\\:\\ 0\\.014378011332276498\ \(0\)\
\-\ known\\:\\ 0\\.014307148595046663\ \(0\)\
\-\ such\\:\\ 0\\.014134035925083874\ \(0\)\
\-\ 1\\.\\:\\ 0\\.014122694001574607\ \(0\)\
\-\ tenderness\\:\\ 0\\.013750858851225572\ \(0\)\
\-\ usually\\:\\ 0\\.013729779120988142\ \(0\)\
\-\ negative\\:\\ 0\\.013503281277115736\ \(0\)\
\-\ region\\:\\ 0\\.012770376863700066\ \(0\)\
\-\ 4\\:\\ 0\\.012597734948037276\ \(0\)\
\-\ y\\/o\\:\\ 0\\.012521846718622437\ \(0\)\
\-\ are\\:\\ 0\\.012326707645815891\ \(0\)\
\-\ one\\:\\ 0\\.012252547001643618\ \(0\)\
\-\ therapy\\:\\ 0\\.012088046540955624\ \(0\)\
\-\ mild\\:\\ 0\\.011906102930852576\ \(0\)\
\-\ patients\\:\\ 0\\.011701452906698549\ \(0\)\
\-\ both\\:\\ 0\\.011546031696751963\ \(0\)\
\-\ over\\:\\ 0\\.011511336455766998\ \(0\)\
\-\ metastatic\\:\\ 0\\.011381531236063969\ \(0\)\
\-\ more\\:\\ 0\\.011307811160381832\ \(0\)\
\-\ physical\\:\\ 0\\.011092620473974805\ \(0\)\
\-\ 3\\:\\ 0\\.0105871720989764\ \(0\)\
\-\ posterior\\:\\ 0\\.010421367982552637\ \(0\)\
\-\ other\\:\\ 0\\.010421367982552637\ \(0\)\
\-\ can\\:\\ 0\\.010255144722058568\ \(0\)\
\-\ lower\\:\\ 0\\.010168582377586574\ \(0\)\
\-\ exam\\:\\ 0\\.009932454708727714\ \(0\)\
\-\ may\\:\\ 0\\.009917081316921289\ \(0\)\
\-\ have\\:\\ 0\\.009790677663307363\ \(0\)\
\-\ lateral\\:\\ 0\\.009770730400129896\ \(0\)\
\-\ female\\:\\ 0\\.009295027891258379\ \(0\)\
\-\ presents\\:\\ 0\\.009236213203745638\ \(0\)\
\-\ lesion\\:\\ 0\\.009209286910055315\ \(0\)\
\-\ treatment\\:\\ 0\\.009151412484660778\ \(0\)\
\-\ to\\:\\ 0\\.009038478485565847\ \(0\)\
\-\ the\\:\\ 0\\.00804625466529039\ \(0\)\
\-\ on\\:\\ 0\\.007660222353073312\ \(0\)\
\-\ \\(\\:\\ 0\\.007644039431151963\ \(0\)\
\-\ \\)\\:\\ 0\\.007550663408606403\ \(0\)\
\-\ by\\:\\ 0\\.00752841747748611\ \(0\)\
\-\ normal\\:\\ 0\\.007087896585180428\ \(0\)\
\-\ be\\:\\ 0\\.0069722577954705245\ \(0\)\
\-\ as\\:\\ 0\\.006839034422720253\ \(0\)\
\-\ ct\\:\\ 0\\.006324357954455254\ \(0\)\
\-\ an\\:\\ 0\\.006252195049125555\ \(0\)\
\-\ is\\:\\ 0\\.005950166967034133\ \(0\)\
\-\ pain\\:\\ 0\\.005521736336141453\ \(0\)\
\-\ or\\:\\ 0\\.00529906216382914\ \(0\)\
\-\ of\\:\\ 0\\.004931377811555065\ \(0\)\
\-\ and\\:\\ 0\\.003809714407031078\ \(0\)\
\-\ in\\:\\ 0\\.002229614974287063\ \(0\)\
\-\ \\.\\:\\ 0\\.002066110566512217\ \(0\)\
\-\ with\\:\\ 0\\.001857209144283964\ \(0\)\
\-\ \\,\\:\\ 0\\.0014323283889803565\ \(0\)\
